Written answers

Thursday, 11 March 2021

Department of Health

Vaccination Programme

Photo of Colm BurkeColm Burke (Cork North Central, Fine Gael)
Link to this: Individually | In context | Oireachtas source

229. To ask the Minister for Health if NPHET has considered if all cohorts will receive a vaccine (details supplied) if approved by the EMA; if not, if the vaccine will be limited to certain cohorts; and if he will make a statement on the matter. [13711/21]

Photo of Stephen DonnellyStephen Donnelly (Wicklow, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

COVID-19 vaccines can only be approved and used if they comply with all the requirements of quality, safety and efficacy set out in the EU pharmaceutical legislation. Any authorised vaccine will be subject to ongoing monitoring in Ireland by the Health Product Regulatory Authority (HPRA).

Following the recommendation for use of vaccines against COVID-19 by the European Medicines Agency (EMA) and authorisation for use by the European Commission, the National Immunisation Advisory Committee (NIAC) develops guidance for their use in Ireland which is contained in the Immunisation Guidelines for Ireland. These guidelines are continuously updated and includes guidance on all new vaccines as they are approved for use in Ireland.

Photo of Colm BurkeColm Burke (Cork North Central, Fine Gael)
Link to this: Individually | In context | Oireachtas source

230. To ask the Minister for Health if a dedicated phone and email line will be instituted by his Department to answer queries from those with serious and underlying conditions seeking clarity as to which cohort they fall under in the Covid-19 vaccination schedule; and if he will make a statement on the matter. [13712/21]

Photo of Stephen DonnellyStephen Donnelly (Wicklow, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

The COVID-19 Vaccine Allocation Strategy sets out a provisional list of groups for vaccination. The Strategy was developed by the National Immunisation Advisory Committee (NIAC) and my Department , endorsed by the National Public Health Emergency Team (NPHET), and approved by Government on 8 December 2020.

Vaccine allocation is a matter for my Department and further information is available here: .

The rollout of the COVID-19 vaccination programme is the responsibility of the HSE.

The aim of the COVID-19 vaccination programme is to ensure, over time, that vaccine will become available to vaccinate all of those for whom the vaccine is indicated. Given that there will be initially limited vaccines available, it will take some time for all to receive those vaccines and that has necessitated an allocation strategy to ensure that those most at risk of death and serious illness receive the vaccine first.

The priority is to first vaccinate and protect directly the most vulnerable amongst us, that is, those most likely to have a poor outcome if they contract the virus. The priority is to directly use vaccines to save lives and reduce serious illness, hence the focus on the over 65 year old cohort in long term residential care facilities, and healthcare workers in frontline services often caring for the most vulnerable.

Vaccination of those aged 70 and older (in the following order: 85 and older, 80-84, 75-79, and 70-74) began in February.

On the 23rdof February, the Minister for Health announced an update to Ireland’s COVID-19 Vaccine Allocation Strategy.

In comprising the initial Vaccine Allocation Strategy, the NIAC listed several conditions associated with increased risk of severe disease and death. In the intervening period, national and international evidence has become available which has enabled a more detailed analysis of underlying conditions that may increase the risk of developing severe disease or death.

The NIAC has now been able to more comprehensively identify those medical conditions and to distinguish between those which place a person at very high or high risk of severe disease if they contract the virus. Medical conditions and the magnitude of the risk they pose will continue to be monitored and periodically reviewed.

The NIAC continues to monitor data around this disease and indeed emerging data on effectiveness of vaccines on a rolling basis.

Further details are available at the following link:

.

In relation to the categories of very high risk and high risk conditions, this list is not exhaustive. It may also include people who have been classed as at very high risk, based on clinical judgement and an assessment of need. It is recommend that the individuals concerned discuss this with their treating physician who is in the best position to give appropriate advice.

Comments

No comments

Log in or join to post a public comment.